Health Care Down as Novo Nordisk, CVS Slide — Health Care Roundup
Health-care companies fell after lackluster earnings for an obesity-drug maker and from one major drug-store chain.
Novo Nordisk shares plunged after its blockbuster Wegovy weight-loss drug missed sales expectations after the pharmaceutical giant offered bigger discounts to U.S. buyers.
CVS Health's Medicare business continued to struggle in the second quarter, fueling yet another cut to its full-year earnings outlook, a new $2 billion cost-cutting plan, and the departure of a top executive.
Medtronic disclosed that the Food and Drug Administration approved Simplera, the medical technology company's continuous glucose monitor.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
August 07, 2024 17:54 ET (21:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States